IL-27 was further demonstrated to exert antitumor activity against poorly immunogenic B16F10 melanoma, which is mediated through NK cells but not CTL [10], and also against NK cell–resistant head and neck squamous cell carcinoma SCCVII through NK cell–mediated antibody-dependent cellular cytotoxicity (ADCC) [11]. This evidence concerns the gene IL27 and melanoma.